Objective: The determinants of subarachnoid hemorrhage (SAH) volume and an atypical pattern of blood are not clear. Our objective was to determine if reduced platelet activity on admission and abnormal venous drainage are associated with greater SAH volume.
activity because they are associated with more bleeding and worse outcome after intraparenchymal hemorrhage. 13, 14 Identification of determinants of SAH volume would be helpful to identify which patients likely have PM-SAH (and its attendant excellent prognosis) or an occult aneurysm. We tested the hypotheses that reduced platelet activity and altered venous drainage are associated with a greater volume of bleeding in patients with nonaneurysmal SAH. METHODS We prospectively identified patients from November 2006 through May 2011. SAH was diagnosed by typical clinical symptoms and acute hemorrhage detected on routine CT scanning. Patients with permanent coma, lack of intracranial blood flow due to intracranial catastrophe from aneurysm rupture, or an identified aneurysm were excluded. SAH due to trauma, arteriovenous malformation rupture, vasculitis, metastasis, and other structural lesions were excluded. All patients were admitted to a dedicated neurologic intensive care unit and evaluated by a certified neurologist and neurosurgeon.
All patients were evaluated with high-quality CT angiography (CTA) or catheter angiography in-house to detect an occult aneurysm (all but one patient underwent both on admission), interpreted by a certified neuroradiologist.
Multidetector CTA acquisition was performed according to standard protocol on either 16-or 64-section helical CT scanners. The scans were performed from the C1 vertebral body base to the vertex with the following parameters: pitch 0.5, collimation 1 mm, slice thickness 1 mm, 340 mAs, 120 kVp, field of view 20 cm, matrix 512 ϫ 512, and 65-mL nonionic contrast agent administered by power injector at 4 mL per second into an antecubital vein after a test bolus was given to determine the scan delay. The analysis of venous drainage was performed in 30 of 31 (97%) patients with the study performed. In 13 of the 30 cases 3-mm-thick maximum intensity projection axial reconstructions were available. Drainage was classified as previously described by others 11, 15 as normal, discontinuous on the left or right, or primitive by a single certified neuroradiologist (A.J.N.) who was blinded to clinical variables and outcomes.
Standard protocol approvals, registrations, and patient consents. The study was approved by the Institutional Review
Board and all patients or a legally authorized representative gave written consent.
Clinical variables were prospectively collected. We recorded baseline demographic and past medical history data onto standardized forms. The intensive care unit pharmacist routinely performed medication reconciliation with the patient and surrogates, and aspirin use was prospectively recorded. (No patient was known to take clopidogrel.) We recorded a history of hypertension as documented outpatient blood pressure Ͼ135/90 mm Hg or prescribed antihypertensive medication, and a history of diabetes as documented outpatient diagnosis or prescribed hypoglycemic medication. A history of coronary artery disease was defined as a history of revascularization or documented myocardial ischemia. We prospectively recorded if an external ventricular drain (EVD) was required for clinical hydrocephalus, and the occurrence of clinical vasospasm (new focal neurologic deficit or depressed mental status without other explanation).
We routinely measured platelet activity on admission in our certified clinical laboratory. The VerifyNow-ASA (Accumetrics, CA) is designed to measure platelet function based upon the ability of activated platelets to bind fibrinogen. Fibrinogencoated microparticles aggregate in whole blood in proportion to the number of unblocked platelet GPIIb/IIIa receptors. Light transmittance increases as activated platelets bind and aggregate fibrinogen-coated beads. The instrument measures this change in optical signal caused by aggregation. The results are reported as aspirin reaction units (ARU), with Յ550 ARU indicative of reduced platelet activity due to aspirin. 16 SAH volumes from the diagnostic CT scan were obtained with Analyze software (Mayo Clinic, Rochester, MN) with a semiautomated process. Industry-standard DICOM images (from ours or a referring hospital) were loaded onto a workstation. Subarachnoid blood was identified by increased density relative to surrounding tissue on every axial slice by Houndsfield units, and the perimeter was automatically drawn by the software program (figure e-1 on the Neurology ® Web site at www.neurology.org). The technique has an excellent interrater reliability 13 and has been used as an endpoint in studies of intracerebral hemorrhage. 17 To validate this technique in this population, 2 examiners independently calculated SAH volumes from a representative sample of 12 patients with volumes from Ͻ1 mL through Ͼ25 mL, and excellent correlation was found (Spearman rho ϭ 0.96, p Ͻ 0.001). We prospectively rated the severity of SAH on the diagnostic CT with a validated semiquantitative scale. 18 Functional outcomes were obtained at 14 days or discharge (whichever was first) and 3 months with the modified Rankin Scale (mRS), 19 a validated functional scale from 0 (no symptoms) to 6 (death). We used a validated questionnaire 20 to ascertain the mRS after discharge, usually by telephone.
SAH volumes were not normally distributed, so they are presented as median (Q1-Q3). Groups were compared with Mann-Whitney U or Kruskal-Wallis H as appropriate. Categorical data were compared with 2 , and odds ratios computed with Mantel-Haenszel estimates. Correlations were performed with Spearman rho. p Յ 0.05 Was considered significant. All tests were 2-tailed. Statistical calculations were made with standard commercial software (IBM SPSS statistics v. 19, Armonk, NY).
RESULTS
Demographics of the cohort are shown in the table. Thirty (97%) patients underwent an angiogram on admission, and 25 (81%) at least 1 additional delayed angiogram, and 3 (10%) a third angiogram prior to discharge. No patient had a history of atrial fibrillation, warfarin use, or clopidogrel use. Any known aspirin use was associated with increased odds of reduced platelet activity: odds ratio 14 (95% confidence interval 1.3-150.9, p ϭ 0.049).
For the entire cohort, the measured SAH volume was 11.5 (3.8 -19.5) mL. Less platelet activity was correlated with a greater SAH volume (Spearman rho Ϫ0.526, p ϭ 0.007). Patients with reduced platelet activity had more SAH volume than patients with normal platelet activity, 17.5 (10.6 -20.9) vs 6.1 (2.3-15.3) mL ( p ϭ 0.046, figure 1) . The results were similar for patients known to take any aspirin vs not, 18.5 (5.1-21.9) vs 11.2 (3.8 -16.4) mL ( p ϭ 0.2). The 25 (81%) patients prospectively noted as having thick (modified Fisher grade III) 18 figure 1 ). Venous drainage and reduced platelet activity were not correlated ( p ϭ 0.6). The availability of maximum intensity projection images was not associated with the classification of venous drainage or SAH volume.
Eleven (35%) patients required placement of an EVD for clinical hydrocephalus. These patients had more SAH than those who did not undergo EVD placement, 16.4 (11.5-20.5) vs 5.4 (2.7-16.4) mL ( p ϭ 0.009). One patient developed symptomatic vasospasm.
Greater SAH volume ( p ϭ 0.02) and reduced platelet activity ( p ϭ 0.04) were related to an in-creased mRS at 14 days (figure 2). At 3 months only 2 patients had mild disability (mRS 2) and only 1 was nonindependent (mRS 4), while the rest had no symptoms. No patient was eventually found to have an intracranial aneurysm. DISCUSSION We found that reduced platelet activity (consistent with aspirin use) and discontinuous venous drainage were associated with more SAH in noncomatose patients without an identifiable aneurysm. These results are intuitive because aspirin is associated with more bleeding and worse acute outcomes in patients with intraparenchymal hemorrhage, 13, 14 while discontinuous venous drainage might lead to more severe bleeding if there is a venous rupture. These data may explain why a substantial proportion of patients with SAH and no identifiable aneurysm have more SAH than would be expected ("diffuse" or "thick" PM-SAH as opposed to typical PM-SAH) and may have a course complicated by hydrocephalus or vasospasm. 9 These data suggest that not all patients with thick SAH require multiple invasive imaging studies if there is another explanation (measured reduced platelet activity, known aspirin use, or discontinuous venous drainage).
Greater SAH volume was associated with more disability at 14 days and placement of an EVD for hydrocephalus, and such a result might be reasonably expected. While more SAH volume was associated with the perceived clinical need for an EVD, this is not strictly the same as hydrocephalus. Even with the more complicated acute course, no patients died and clinical outcomes were excellent, consistent with the known history of PM-SAH. 2 Despite the increased SAH volume with reduced platelet activity, the lack of bleeding from an arterial source makes an excellent outcome likely.
While aspirin was associated with reduced platelet activity, it was not significantly associated with greater SAH volume. Aspirin is unlikely to be the only antiplatelet medication taken, and we the patient may not have reported a single dose for headache. Over-the-counter pain medications (e.g., ibuprofen) will also lead to reduced platelet activity 21 and might reasonably be taken for the headache that accompanies PM-SAH. Aspirin and ibuprofen are not detected on routine toxicology screens, and a disoriented patient might not be able to provide an over-thecounter medication history, so point-of-care testing is likely to be more sensitive. (We have made a similar observation in patients with intraparenchymal hemorrhage. 22 ) Measured salicylate levels might have been helpful to detect surreptitious aspirin use.
We prospectively graded the pattern of subarachnoid blood, 18 but did not attempt to define the pat- tern of subarachnoid blood as perimesencephalic or diffuse because the inter-rater reliably of such a comparison is not excellent. 8 Measuring the volume of subarachnoid blood with a validated technique may be more informative than its pattern, and we demonstrated a high inter-rater correlation. While some clinicians might not consider patients with thick SAH or a diffuse pattern of SAH to have PM-SAH, we found that such patients usually have its benign clinical course and outcome. We excluded permanently comatose patients because PM-SAH typically occurs in good-grade patients. 1 The inability to find an aneurysm in a comatose patient with SAH may indicate there is no cerebral blood flow, a requirement for angiography or CTA, and this may be a different patient population from the one described here. In our registry, the outcome for 6 such patients was death by neurologic criteria. Two such other excluded patients were dependent at 14 days, mRS 4 and 5, and survived to discharge but their surrogates declined consent to record identifiers and obtain follow-up. This patient population may require further study.
Strengths of this work include prospective identification of patients with outcomes after discharge, routine measurement of platelet activity, routine performance of CTA with interpretation of venous drainage by a blinded certified interpreter with a previously published classification, medication reconciliation on admission, and volumetric analysis of CT scans with a validated technique. Potential weaknesses of these data include the ascertainment of patients at only one center and the modest number of patients. The diagnosis of nonaneurysmal SAH, however, should not substantially vary between institutions. Not all methods of platelet activity testing are equivalent; the method we used performs closest to platelet aggregometry, 23 is Food and Drug Administration-approved to detect an aspirin effect, is relatively inexpensive, and can be easily measured during off hours. These tabletop assays should have excellent test-retest reliability when calibrated per the manufacturer instructions. We did not routinely measure salicylate levels, although this might be helpful to exclude aspirin use. The interpretation of venous drainage from CTA should also be similar at different institutions. We only analyzed the diagnostic CT, not subsequent CT scans, and so have no data on the evolution of SAH volumes over time. We relied on published methods for the analysis of venous drainage from CT, but did not perform dedicated catheter venograms, which might be more accurate for the detection of aberrant venous drainage.
We found that reduced platelet activity and discontinuous venous drainage were associated with Subarachnoid hemorrhage (SAH) volume, stratified by venous drainage (11 normal, 9 with 1 discontinuous, 6 with bilateral discontinuous) and platelet activity as <550 (consistent with an aspirin effect) or >550 aspirin reaction units SAH volume was greater with 1 or 2 discontinuous venous drainage systems and reduced platelet activity. The median is represented by a horizontal line, Q1 and Q3 values at the ends of the box, and 5th and 95th percentiles at the I-bars. See text for details.
Figure 2 Subarachnoid hemorrhage (SAH) volume stratified by disability at 14 days
Greater SAH volume was associated with increased 14-day disability (overall p ϭ 0.02; for comparison shown p Ͻ 0.001). mRS ϭ modified Rankin Scale.
more SAH in patients without an identifiable aneurysm. When thick 18 SAH is seen on CT in a patient without an identifiable aneurysm, reduced platelet activity or discontinuous venous drainage are potential explanations and may obviate the need for serial invasive imaging studies; even if clinical hydrocephalus leads to EVD placement, such patients are likely to have an excellent outcome.
